Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of SNPs in CYP450 in Chloroquine/PrimaquinePlasmodium VivaxMalaria Treatment

21 Oct 2016

Abstract excerpt

BACKGROUND: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region. AIMS: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS & METHODS: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Multiple Myeloma Research and Treatments
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27767381
DOI: 10.2217/pgs-2016-0131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of SNPs in CYP450 in Chloroquine/PrimaquinePlasmodium VivaxMalaria TreatmentPMID 27767381Read ↗

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy.Semantic proximity Read ↗

Polymorphisms in Cytochrome P450 genes: implications for Plasmodium vivax malaria treatment in Brazil.Semantic proximity Read ↗

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.Semantic proximity Read ↗

Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.Semantic proximity Read ↗

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Semantic proximity Read ↗

CYP2C8 and Antimalaria Drug EfficacySemantic proximity Read ↗

The pharmacogenetics of antimalaria artemisinin combination therapy.Semantic proximity Read ↗

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.Semantic proximity Read ↗

Coverage Rate of ADME Genes: Application to CYP2C8, CYP2D6 and CYP3A Genes for Personalized Chloroquine Treatment Against CoronavirusSemantic proximity Read ↗

Influence of Cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in ZanzibarSemantic proximity Read ↗

Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.